Clinical trials · Denver, CO
Leukemia clinical trials in Denver
We’re tracking 67 recruiting leukemia studies with a site in or near Denver — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Denver
- NCT05082519RecruitingPhase 2
Calorie reduction and activity to help chemo work in B-ALL
This Phase 2 study tests whether eating fewer calories and doing activity safely can make chemotherapy work better for children and young adults with newly diagnosed B-ALL. It aims to reduce chemo resistance, meaning help leukemia respond more strongly to treatment.
Denver, ColoradoAges 10–25 - NCT05237258Recruiting
Compare palliative care approaches for people with high-risk AML
This study tests a specialized (targeted) palliative care program versus usual oncology care for people hospitalized with high-risk acute myeloid leukemia (AML). The goal is to see if this palliative approach improves comfort, support, and care planning during intensive treatment.
Denver, ColoradoAges 18–120 - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Denver, ColoradoAges Up to 22 years - NCT04988555RecruitingPhase 1/Phase 2
Study of an investigational drug for high-risk acute leukemia
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
Denver, ColoradoAges 12 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Denver, ColoradoAges 18 years+ - NCT05735184RecruitingPhase 1
Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
Denver, ColoradoAges 18 years+ - NCT06001788RecruitingPhase 1
Ziftomenib for relapsed or refractory acute myeloid leukemia
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
Denver, ColoradoAges 18 years+ - NCT06514794RecruitingPhase 2
CAR-T cell therapy for T-cell leukemia and lymphoma
This trial tests a new CAR-T cell therapy (WU-CART-007) made from donor cells that target a protein called CD7 on cancer cells. It is for children and adults with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or is still present after treatment.
Denver, ColoradoAges 1 year+ - NCT06177067RecruitingPhase 1
Study of 3 drugs for young AML patients with genetic changes
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
Aurora, ColoradoAges 1–30 - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Aurora, ColoradoAges 6 months–25 years - NCT05535855RecruitingPhase 1
UCD19 CAR T for adult ALL with MRD in remission
This early-phase study tests a personalized immune-cell treatment (CAR T) for adults with B-cell acute lymphoblastic leukemia (ALL) who still have tiny amounts of cancer detectable by a special test called MRD. It aims to improve outcomes for people who are in first remission but not completely “cancer-free” by MRD testing.
Aurora, ColoradoAges 18 years+ - NCT05183035RecruitingPhase 3
Venetoclax for relapsed childhood AML
This trial studies venetoclax in children and young adults whose acute myeloid leukemia (AML) has come back. It aims to see how well this treatment controls the leukemia after earlier therapies.
Aurora, ColoradoAges 4 weeks–21 years - NCT05401097RecruitingPhase 2
Venetoclax plus IDH-targeted pills for AML patients who can’t get intensive chemo
This Phase 2 trial tests different ways of using medicines that target IDH mutations (IDH-targeted treatment) plus venetoclax in people newly diagnosed with IDH-mutated AML. It’s designed for patients who cannot safely receive intensive induction chemotherapy, to see which approach works best and is tolerable.
Aurora, ColoradoAges 18 years+ - NCT06376162RecruitingPhase 1
Ziftomenib with chemo for kids with relapsed acute leukemia
This trial tests a new targeted drug called ziftomenib combined with chemotherapy for children whose leukemia (with specific genetic changes) has come back or is not responding to treatment. The goal is to see if this combination can help control the cancer.
Aurora, ColoradoAges birth–21 years - NCT07347418RecruitingPhase 1
CD64 CAR T cell therapy for relapsed or refractory AML
This trial tests a type of immunotherapy called CAR T cells that target a protein called CD64 on leukemia cells. It is for adults with AML that has come back or not responded to treatment, including venetoclax.
Aurora, ColoradoAges 18 years+ - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
Aurora, ColoradoAges Up to 12 months - NCT07586618RecruitingPhase 1
New Drug 4A10 for Hard-to-Treat Lymphoblastic Leukemia or Lymphoma
This is an early-stage study testing a new experimental drug (4A10) in patients whose acute lymphoblastic leukemia or lymphoblastic lymphoma has returned or stopped responding to standard treatments. Researchers want to learn if the drug is safe and how it works in the body.
Aurora, ColoradoAges 18 years+ - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Aurora, ColoradoAges 1–18 - NCT05287568RecruitingPhase 1
Testing azacitidine plus venetoclax for acute myeloid leukemia
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
Aurora, ColoradoAges 18–100 - NCT06428019RecruitingPhase 3
Comparing drug combinations for untreated CLL or SLL
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
Aurora, ColoradoAges 18 years+ - NCT06429449RecruitingPhase 1
Mitoxantrone for venetoclax-resistant AML
This trial tests a re-purposed drug, mitoxantrone, for people whose AML has not responded to or has come back after standard frontline treatment. The goal is to see if this older drug can help overcome resistance to venetoclax.
Aurora, ColoradoAges 18–80 - NCT06549790RecruitingPhase 1
Study of NMS-03597812 for relapsed or refractory AML
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
Aurora, ColoradoAges 18 years+ - NCT04972942RecruitingPhase 1
Immunotherapy for high-risk T-cell blood cancers after transplant
This Phase 1 study tests a targeted immune treatment given after strong pre-treatment (myeloablative chemo plus total-body radiation) before or along with an allogeneic stem cell transplant. It may help prevent the cancer from coming back in young people with high-risk T-cell ALL or certain T-cell lymphomas.
Aurora, ColoradoAges Up to 39 years - NCT06124157RecruitingPhase 2
Targeted therapy plus chemo for children with Ph+ or Ph-like B-ALL
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
Aurora, ColoradoAges 1 year–46 years
Hear when a new Leukemia trial opens near Denver, CO
We’ll email you when one opens near Denver, CO — at most once a week, no account needed, unsubscribe anytime.
Leukemia trials in other cities
Where these studies are running near Denver
Institutions with a site for the recruiting leukemia studies listed above.
- Children's Hospital Colorado · 10 studies
- Colorado Blood Cancer Institute · 5 studies
- UCHealth University of Colorado Hospital · 4 studies
- Rocky Mountain Cancer Centers · 2 studies
- University of Colorado · 2 studies
- University of Colorado Anschutz Medical Campus · 2 studies
- Children's Hospital Colordao
- Presbyterian/St. Luke's Medical Center
What taking part in a leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting leukemia studies in Colorado.
Common questions
- Are there leukemia clinical trials near Denver?
- Yes. We're currently tracking 67 recruiting leukemia studies with a site near Denver, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a leukemia study near Denver?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Denver to take part?
- Not necessarily. These studies have a site near Denver, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New leukemia studies open near Denver regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.